News and Events
Study available at U-M evaluates reparixin in combination with paclitaxel for metastatic triple-negative breast cancer
ANN ARBOR, Mich. – An international clinical trial is testing an investigational study drug designed to target cancer stem cells in women with triple-negative breast cancer.
Triple-negative is the most aggressive kind of breast cancer. Triple negative tumors are negative for estrogen receptor, progesterone receptor and the HER2 protein. Because treatments that target these proteins would not work in triple negative breast cancer, the main treatment for it is chemotherapy.
A new paper looks at how MRI and a clear understanding of the functional anatomy around the prostate can allow radiation oncologists to plan a course of treatment for patients with prostate cancer that spares these critical structures.